Chi KN, et al. - Through a double-blind, phase 3 trial, the researchers sought to determine the radiographic progression–free survival and overall survival for metastatic, castration-sensitive prostate cancer patients when apalutamide (an inhibitor of the ligand-binding domain of the androgen receptor) was added to androgen-deprivation therapy (ADT) vs placebo with ADT. For this study, 525 patients received apalutamide plus ADT and 527 received placebo plus ADT. Greater overall survival and radiographic progression–free survival at 24 months was seen in the apalutamide group vs the placebo group. No significant difference in the side-effect profile was noted between the two groups.